Updated advice on selecting TKI therapy, managing side effects and vascular risk and stopping treatment in patients with chronic myeloid leukaemia (CML) has been published by the British Society for Haematology. It updates the previous guidance from 2007 and covers several aspects not really addressed by other recommendations, said guideline author Dr Graeme Smith in ...
New CML guidance provides more info on managing risks
By Emma Wilkinson
20 Aug 2020